(Q33207883)

23 July 2017

1 reference

title

Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer (English)

1 reference

23 July 2017

1 reference

James E Frampton

1

1 reference

23 July 2017

Stephanie E Easthope

series ordinal

2

1 reference

23 July 2017

publication date

1 January 2004

1 reference

23 July 2017

1 reference

23 July 2017

volume

64

1 reference

23 July 2017

issue

21

1 reference

23 July 2017

page(s)

2475-2492

1 reference

Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.

23 July 2017

cites work

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia

1 reference

12 December 2020

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

12 December 2020

Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer

1 reference

12 December 2020

Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

12 December 2020

Targeting the epidermal growth factor receptor in non-small cell lung cancer.

1 reference

12 December 2020

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale

1 reference

12 December 2020

Targeting the epidermal growth factor receptor

1 reference

12 December 2020

Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.

1 reference

12 December 2020

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.

1 reference

12 December 2020

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

1 reference

12 December 2020

Can current treatments for advanced non-small-cell lung cancer be improved?

1 reference

12 December 2020

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

12 December 2020

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

1 reference

12 December 2020

Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Tolerability of gefitinib in patients receiving treatment in everyday clinical practice

1 reference

12 December 2020

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

1 reference

12 December 2020

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).

1 reference

12 December 2020

Gefitinib, a novel, orally administered agent for the treatment of cancer

1 reference

12 December 2020

The benefits of achieving stable disease in advanced lung cancer.

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience

1 reference

12 December 2020

Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed

1 reference

12 December 2020

1 reference

12 December 2020

Emerging drugs for non-small cell lung cancer

1 reference

12 December 2020

Gefitinib: phase II and III results in advanced non-small cell lung cancer

1 reference

12 December 2020

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

12 December 2020

Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients

1 reference

12 December 2020

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

1 reference

12 December 2020

Lung cancer: a review

1 reference

12 December 2020

ZD1839 ('Iressa') as an anticancer agent

1 reference

12 December 2020

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

1 reference

12 December 2020

Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.

1 reference

12 December 2020

New directions for ZD1839 in the treatment of solid tumors

1 reference

12 December 2020

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

1 reference

12 December 2020

Docetaxel for previously treated non-small-cell lung cancer

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

1 reference

12 December 2020

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

12 December 2020

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?

1 reference

12 December 2020

10.2165/00003495-200464210-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

23 July 2017

1031141617

0 references

1 reference